Cybin Inc.
HMNC Brain Health and Develco Pharma have announced promising top-line results from the Phase II proof-of-concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01)...
The trial MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has advanced to the next implementation phase.
Follow-up data from a Phase III clinical trial shows that MDMA therapy could hold promise for millions suffering from the condition.
Psyched Wellness and the National Research Council of Canada (NRC) have announced preliminary data from studies of the neuroprotective and anti-inflammatory properties of AME-1.
The first patient has now been enrolled on to the Entheon Biomedical Phase 1 Study of DMT.
One company is hoping to combine the altered state of the psychedelic experience with the unreal environment of virtual reality (VR) to improve anxiety.
Mydecine Innovations has reported a positive pre-investigational new drug (IND) meeting with America’s Food and Drug Administration (FDA) regarding its psychedelic compound for smoking cessation.
A company is addressing concerns over the medical application of microdosing by developing a molecule that could eliminate the potential risk of heart damage.
Some patients hospitalised with severe suicidal thoughts could benefit from ketamine treatment.
